Molecular detection of prostate cancer: A role for GSTP1 hypermethylation

European Urology

Volumn 46, Issue 5, 2004, Pages 660-669

  Henrique, Rui ^a,b   Jerónimo, Carmen ^a  

^a Port Oncology Institute Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Cancer detection; Epigenetics; GSTP1; Methylation; Molecular markers; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER;

BODY FLUID; CANCER DIAGNOSIS; CANCER GENETICS; CANCER STAGING; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE MARKER; DNA METHYLATION; EPIGENETICS; GENE; GENE LOCUS; GENE MUTATION; GENE SILENCING; GENETIC MARKER; GLUTATHIONE S TRANSFERASE P1 GENE; HUMAN; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVIEW; STATISTICAL SIGNIFICANCE;

DNA METHYLATION; DNA, NEOPLASM; GLUTATHIONE TRANSFERASE; HUMANS; MALE; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 5144220196     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.06.014     Document Type: Review

References (100)

1. A. Jemal, R.C. Tiwani, T. Murray, A. Ghafoor, A. Samuels, and E. Ward Cancer statistics, 2004 CA Cancer J Clin. 54 2004 8 29
2. M. Han, A.W. Partin, C.R. Pound, J.I. Epstein, and P.C. Walsh Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience Urol Clin North Am. 28 2001 555 565
3. G.K. Zagars, A. Pollack, and A.C. von Eschenbach Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era Cancer 79 1997 1370 1380
4. C.M. Moinpour, M.J. Savage, A. Troxel, L.C. Lovato, M. Eisenberger, and R.W. Veith Quality of life in advanced prostate cancer: results of a randomized therapeutic trial J Natl Cancer Inst. 90 1998 1537 1544
5. M.K. Brawer Screening for prostate cancer Semin Surg Oncol. 18 2000 29 36
6. D.E. Neal, and J.L. Donovan Prostate cancer: to screen or not to screen? Lancet Oncol. 1 2000 17 24
7. W.J. Catalona, P.C. Southwick, K.M. Slawin, A.W. Partin, M.K. Brawer, and R.C. Flanigan Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging Urology 56 2000 255 260
8. W.J. Catalona, D.S. Smith, and D.K. Ornstein Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements JAMA 277 1997 1452 1455
9. F.H. Schroder, I. van der Cruijsen-Koeter, H.J. de Koning, A.N. Vis, R.F. Hoedemaeker, and R. Kranse Prostate cancer detection at low prostate specific antigen J Urol. 163 2000 806 812
10. J.I. Epstein Diagnosing adenocarcinoma of the prostate on needle biopsy J.I. Epstein Prostate biopsy interpretation 2nd ed. 1995 Lippincott-Raven New York 87-132
11. J.I. Epstein, P.C. Walsh, and F. Sanfilippo Clinical and cost impact of second opinion pathology review of prostate needle biopsies prior to radical prostatectomy Am J Surg Pathol. 20 1996 851 857
12. D.W. Keetch, W.J. Catalona, and D.S. Smith Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values J Urol. 151 1994 1571 1574
13. D.M. Steinberg, J. Sauvageot, S. Piantadosi, and J.I. Epstein Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings Am J Surg Pathol. 21 1997 566 576
14. D.F. Gleason, and G.T. Mellinger Veterans Administration Cooperative Urological Research group Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol. 111 1974 58 64
15. W.C. Allsbrook Jr., K.A. Mangold, M.H. Johnson, R.B. Lane, C.G. Lane, and J.I. Epstein Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist Hum Pathol. 32 2001 81 88
16. D. Sidransky Emerging molecular markers of cancer Nat Rev Cancer. 3 2002 210 219
17. D. Sidransky, A. Von Eschenbach, Y.C. Tsai, P. Jones, I. Summerhayes, and F. Marshall Identification of p53 gene mutations in bladder cancers and urine samples Science 252 1991 706 709
18. D. Sidransky, T. Tokino, S.R. Hamilton, K.W. Kinzler, B. Levin, and P. Frost Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors Science 256 1992 102 105
19. S.M. Dong, G. Traverso, C. Johnson, L. Geng, R. Favis, and K. Boynton Detecting colorectal cancer in stool with the use of multiple genetic targets J Natl Cancer Inst. 93 2001 858 865
20. G. Traverso, A. Shuber, B. Levin, C. Johnson, L. Olsson, and D.J. Schoetz Jr. Detection of APC mutations in fecal DNA from patients with colorectal tumors N Engl J Med. 346 2002 311 320
21. P.E. Jackson, S.Y. Kuang, J.B. Wang, P.T. Strickland, A. Munoz, and T.W. Kensler Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients Carcinogenesis. 24 2003 1657 1663
22. X. Sun, K. Hung, L. Wu, D. Sidransky, and B. Guo Detection of tumor mutations in the presence of excess amounts of normal DNA Nat Biotechnol. 20 2002 186 189
23. R. Montironi, R. Mazzucchelli, D. Stramazzotti, R. Pomante, D. Thompson, and P.H. Bartels Expression of pi-class glutathione S-transferase: two populations of high grade prostatic intraepithelial neoplasia with different relations to carcinoma Mol Pathol. 53 2000 122 128
24. R. Bookstein Tumor suppressor genes in prostate cancer Chung LWK W.B. Isaacs J.W. Simons Prostate Cancer: biology, genetics, and the new therapeutics 1st ed. 2001 Humana Press Totowa (NJ) 61 94
25. W.B. Isaacs, and J.T. Isaacs Molecular genetics of prostate cancer progression D. Raghavan H.I. Scher S.A. Leibel P.H. Lange Principles and practice of genitourinary oncology 1st edition. 1996 Lippincott-Raven Philadelphia 403 408
26. P. Cairns, K. Okami, S. Halachmi, N. Halachmi, M. Esteller, and J.G. Herman Frequent inactivation of PTEN/MMAC1 in primary prostate cancer Cancer Res. 57 1997 4997 5000
27. M. Esteller Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes Eur J Cancer. 36 2000 2294 2300
28. A.P. Bird CpG-rich islands and the function of DNA methylation Nature 321 1986 209 213
29. J.G. Herman, and S.B. Baylin Gene silencing in cancer in association with promoter hypermethylation N Engl J Med. 349 2003 2042 2054
30. J.P. Issa, Y.L. Ottaviano, P. Celano, S.R. Hamilton, N.E. Davidson, and S.B. Baylin Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon Nat Genet. 7 1994 536 540
31. T. Waki, G. Tamura, M. Sato, and T. Motoyama Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples Oncogene 22 2003 4128 4133
32. M. Esteller, and J.G. Herman Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours J Pathol. 196 2002 1 7
33. M. Esteller, L. Catasus, X. Matias-Guiu, G.L. Mutter, J. Prat, and S.B. Baylin hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis Am J Pathol. 155 1999 1767 1772
34. M. Esteller, A. Sparks, M. Toyota, M. Sanchez-Cespedes, G. Capella, and M.A. Peinado Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer Cancer Res. 60 2000 4366 4371
35. M. Esteller, P.G. Corn, S.B. Baylin, and J.G. Herman A gene hypermethylation profile of human cancer Cancer Res. 61 2001 3225 3229
36. C. Jerónimo, H. Usadel, R. Henrique, J. Oliveira, C. Lopes, and W.G. Nelson Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma J Natl Cancer Inst. 93 2001 1747 1752
37. M. Esteller, M. Sanchez-Cespedes, R. Rosell, D. Sidransky, S.B. Baylin, and J.G. Herman Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients Cancer Res. 59 1999 67 70
38. M. Sanchez-Cespedes, M. Esteller, L. Wu, H. Nawroz-Danish, G.H. Yoo, and W.M. Koch Gene promoter hypermethylation in tumors and serum of head and neck cancer patients Cancer Res. 60 2000 892 895
39. K. Kawakami, J. Brabender, R.V. Lord, S. Groshen, B.D. Greenwald, and M.J. Krasna Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma J Natl Cancer Inst. 92 2000 1805 1811
40. W.M. Grady, A. Rajput, J.D. Lutterbaugh, and S.D. Markowitz Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer Cancer Res. 61 2001 900 902
41. C. Jerónimo, H. Usadel, R. Henrique, C. Silva, J. Oliveira, and C. Lopes Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer Urology 60 2002 1131 1135
42. H. Usadel, J. Brabender, K.D. Danenberg, C. Jerónimo, S. Harden, and J. Engles Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer Cancer Res. 62 2002 371 375
43. C. Goessl, H. Krause, M. Muller, R. Heicappell, M. Schrader, and J. Sachsinger Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids Cancer Res. 60 2000 5941 5945
44. S.A. Ahrendt, J.T. Chow, L.H. Xu, S.C. Yang, C.F. Eisenberger, and M. Esteller Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer J Natl Cancer Inst. 91 1999 332 339
45. S.L. Rosas, W. Koch, M.G. da Costa Carvalho, L. Wu, J. Califano, and W. Westra Promoter hypermethylation patterns of p16, O6-methylguanine-DNA- methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients Cancer Res. 61 2001 939 942
46. S.A. Belinsky, K.J. Nikula, W.A. Palmisano, R. Michels, G. Saccomanno, and E. Gabrielson Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95 1998 11891 11896
47. W.A. Palmisano, K.K. Divine, G. Saccomanno, F.D. Gilliland, S.B. Baylin, and J.G. Herman Predicting lung cancer by detecting aberrant promoter methylation in sputum Cancer Res. 60 2000 5954 5958
48. S.A. Belinsky, W.A. Palmisano, F.D. Gilliland, L.A. Crooks, K.K. Divine, and S.A. Winters Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers Cancer Res. 62 2002 2370 2377
49. E. Evron, W.C. Dooley, C.B. Umbricht, D. Rosenthal, N. Sacchi, and E. Gabrielson Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR Lancet 357 2001 1335 1336
50. C. Jerónimo, I. Costa, M.C. Martins, P. Monteiro, S. Lisboa, and C. Palmeira Detection of gene promoter hypermethylation in fine needle washings from breast lesions Clin Cancer Res. 9 2003 3413 3417
51. A. Olek, J. Oswald, and J. Walter A modified and improved method for bisulphite based cytosine methylation analysis Nucleic Acids Res. 24 1996 5064 5066
52. J.G. Herman, J.R. Graff, S. Myohanen, B.D. Nelkin, and S.B. Baylin Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands Proc Natl Acad Sci USA 93 1996 9821 9826
53. C.A. Eads, K.D. Danenberg, K. Kawakami, L.B. Saltz, C. Blake, and D. Shibata A high-throughput assay to measure DNA methylation Nucleic Acids Res. 28 2000 E32
54. C.A. Heid, J. Stevens, K.J. Livak, and P.M. Williams Real time quantitative PCR Genome Res. 6 1996 986 994
55. A.K. Virmani, A. Rathi, U.G. Sathyanarayana, A. Padar, C.X. Huang, and H.T. Cunnigham Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas Clin Cancer Res. 7 2001 1998 2004
56. A.K. Virmani, J.A. Tsou, K.D. Siegmund, L.Y. Shen, T.I. Long, and P.W. Laird Hierarchical clustering of lung cancer cell lines using DNA methylation markers Cancer Epidemiol Biomarkers Prev. 11 2002 291 297
57. B. Coles, and B. Ketterer The role of glutathione and glutathione transferases in chemical carcinogenesis Crit Rev Biochem Mol Biol. 25 1990 47 70
58. W.H. Lee, R.A. Morton, J.I. Epstein, J.D. Brooks, P.A. Campbell, and G.S. Bova Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 91 1994 11733 11737
59. D.S. Millar, K.K. Ow, C.L. Paul, P.J. Russell, P.L. Molloy, and S.J. Clark Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer Oncogene. 18 1999 1313 1324
60. X. Lin, M. Tascilar, W.H. Lee, W.J. Vles, B.H. Lee, and R. Veeraswamy GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells Am J Pathol. 159 2001 1815 1826
61. C. Jerónimo, G. Varzim, R. Henrique, J. Oliveira, M.J. Bento, and C. Silva I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma Cancer Epidemiol Biomarkers Prev. 11 2002 445 450
62. J.D. Brooks, M. Weinstein, X. Lin, Y. Sun, S.S. Pin, and G.S. Bova CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia Cancer Epidemiol Biomarkers Prev. 7 1998 531 536
63. X. Lin, K. Asgari, M.J. Putzi, W.R. Gage, X. Yu, and B.S. Cornblatt Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide Cancer Res. 61 2001 8611 8616
64. W.G. Nelson, A.M. De Marzo, T.L. Deweese, X. Lin, J.D. Brooks, and M.J. Putzi Preneoplastic prostate lesions: an opportunity for prostate cancer prevention Ann N Y Acad Sci. 952 2001 135 144
65. M. Esteller, P.G. Corn, J.M. Urena, E. Gabrielson, S.B. Baylin, and J.G. Herman Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia Cancer Res. 58 1998 4515 4518
66. R. Maruyama, S. Toyooka, K.O. Toyooka, K. Harada, A.K. Virmani, and S. Zochbauer-Muller Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features Cancer Res. 61 2001 8659 8663
67. M.W. Chan, L.W. Chan, N.L. Tang, J.H. Tong, K.W. Lo, and T.L. Lee Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients Clin Cancer Res. 8 2002 464 470
68. J.C. Tchou, X. Lin, D. Freije, W.B. Isaacs, J.D. Brooks, and A. Rashid GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas Int J Oncol. 16 2000 663 676
69. P. Cairns, M. Esteller, J.G. Herman, M. Schoenberg, C. Jerónimo, and M. Sanchez-Cespedes Molecular detection of prostate cancer in urine by GSTP1 hypermethylation Clin Cancer Res. 7 2001 2727 2730
70. C. Goessl, M. Muller, R. Heicappell, H. Krause, B. Straub, and M. Schrader DNA-based detection of prostate cancer in urine after prostatic massage Urology. 58 2001 335 338
71. M.H. Weinstein, and J.I. Epstein Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy Hum Pathol. 24 1993 624 629
72. M.L. Gonzalgo, C.P. Pavlovich, S.M. Lee, and W.G. Nelson Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens Clin Cancer Res. 9 2003 2673 2677
73. W.J. Catalona, J.A. Beiser, and D.S. Smith Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies J Urol. 158 1997 2162 2167
74. C.H. Chon, F.C. Lai, J.E. McNeal, and J.C. Presti Jr. Use of extended systematic sampling in patients with a prior negative prostate needle biopsy J Urol. 167 2002 2457 2460
75. C.I. Suh, T. Shanafelt, D.J. May, K.R. Shroyer, J.B. Bobak, and E.D. Crawford Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer Mol Cell Probes. 14 2000 211 217
76. C. Goessl, M. Muller, R. Heicappell, H. Krause, and K. Miller DNA-based detection of prostate cancer in blood, urine, and ejaculates Ann N Y Acad Sci. 945 2001 51 58
77. S.V. Harden, Z. Guo, J.I. Epstein, and D. Sidransky Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma J Urol. 169 2003 1138 1142
78. S.V. Harden, H. Sanderson, S.N. Goodman, A.A. Partin, P.C. Walsh, and J.I. Epstein Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies J Natl Cancer Inst. 95 2003 1634 1637
79. R. Maruyama, S. Toyooka, K.O. Toyooka, A.K. Virmani, S. Zochbauer-Muller, and A.J. Farinas Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features Clin Cancer Res. 8 2002 514 519
80. M. Yamanaka, M. Watanabe, Y. Yamada, A. Takagi, T. Murata, and H. Takahashi Altered methylation of multiple genes in carcinogenesis of the prostate Int J Cancer. 106 2003 382 387
81. D.F. Jarrard, G.S. Bova, C.M. Ewing, S.S. Pin, S.H. Nguyen, and S.B. Baylin Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer Genes Chromosom Cancer. 19 1997 90 96
82. L.C. Li, H. Zhao, K. Nakajima, B.R. Oh, L.A. Filho, and P. Carroll Methylation of the E-cadherin gene promoter correlates with progression of prostate cancer J Urol. 166 2001 705 709
83. H. Kito, H. Suzuki, T. Ichikawa, N. Sekita, N. Kamiya, and K. Akakura Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer Prostate 49 2001 110 115
84. M. Sasaki, Y. Tanaka, G. Perinchery, A. Dharia, I. Kotcherguina, and S. Fujimoto Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer J Natl Cancer Inst. 94 2002 384 390
85. L. Liu, J.H. Yoon, R. Dammann, and G.P. Pfeifer Frequent hypermethylation of the RASSF1A gene in prostate cancer Oncogene. 21 2002 6835 6840
86. C. Jerónimo, R. Henrique, P.F. Campos, J. Oliveira, O.L. Caballero, and C. Lopes Endothelin B receptor gene hypermethylation in prostate adenocarcinoma J Clin Pathol. 56 2003 52 55
87. K. Woodson, R. Hayes, L. Wideroff, L. Villaruz, and J. Tangrea Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites Prostate 55 2003 199 205
88. A. Padar, U.G. Sathyanarayana, M. Suzuki, R. Maruyama, J.T. Hsieh, and E.P. Frenkel Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation Clin Cancer Res. 9 2003 4730 4734
89. Jerónimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D, et al. Quantitative RARβ2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res., in press.
90. Jerónimo C, Henrique R, Oliveira J, Lobo F, Pais I, Teixeira MR, et al. Aberrant Cellular Retinol-Binding-Protein 1 (CRBP1) gene expression and promoter methylation in prostate adenocarcinoma. J Clin Pathol, in press.
91. S.K. Patra, A. Patra, H. Zhao, and R. Dahiya DNA methylatransferase and demethylase in human prostate cancer Mol Carcinogenesis. 33 2002 163 171
92. R. Etzioni, R. Cha, E.J. Feuer, and O. Davidov Asymptomatic incidence and duration of prostate cancer Am J Epidemiol. 148 1998 775 785
93. R. Etzioni, D.F. Penson, J.M. Legler, D. di Tommaso, R. Boer, and P.H. Gann Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends J Natl Cancer Inst. 94 2002 981 990
94. K. Yamashita, S. Upadhyay, M. Osada, M.O. Hoque, Y. Xiao, and M. Mori Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma Cancer Cell. 2 2002 485 495
95. N. Sato, A. Maitra, N. Fukushima, N.T. van Heek, H. Matsubayashi, and C.A. Iacobuzio-Donahue Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma Cancer Res. 63 2003 4158 4166
96. H. Shi, S. Maier, I. Nimmrich, P.S. Yan, C.W. Caldwell, and A. Olek Oligonucleotide-based microarray for DNA methylation analysis: principles and applications J Cell Biochem. 88 2003 138 143
97. R. Singal, J. van Wert, and M. Bashambu Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells Cancer Res. 61 2001 4820 4826
98. P.S. Rennie, and C.C. Nelson Epigenetic mechanisms for progression of prostate cancer Cancer Metastasis Rev. 17 1998 401 409
99. L. Jackson-Grusby, P.W. Laird, S.N. Magge, B.J. Moeller, and R. Jaenisch Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc Natl Acad Sci USA 94 1997 4681 4685
100. A. Villar-Garea, M.F. Fraga, J. Espada, and M. Esteller Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells Cancer Res. 63 2003 4984 4989